Related Experiment Video
Updated: Sep 25, 2026
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
Treatment Duration and Clinical Response Patterns of Laryngopharyngeal Reflux Disease
Jerome R Lechien1,2,3,4
1Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.
Objective:
To investigate the therapeutic response patterns in terms of duration, resistance, and therapeutic failure in patients with a confirmed LPRD diagnosis.
Study Design:
Prospective study.
Setting:
University hospital.
Methods:
Patients with laryngopharyngeal symptoms and >1 pharyngeal reflux event on 24-h hypopharyngeal-esophageal impedance-pH monitoring were prospectively recruited (European Reflux Clinic, Jan 2017-Oct 2025). Based on LPRD pattern, they received diet/lifestyle measures plus alginate, magaldrate and/or PPIs in successive 3-month courses until significant symptom relief allowed discontinuation. Outcomes (RSS, RSA) and optimal treatment duration, success/weaning rates, and chronicity were assessed.
Results:
A total of 361 consecutive patients completed the evaluations (214 females, 59.3%), with 135 (37.4%), 87 (24.1%), and 139 (38.5%) presenting mild, moderate, and severe reflux disease (IFOS classification), respectively. Of 304 patients with complete follow-up, 105 (34.5%) achieved complete response, occurring primarily at 6 weeks (27.6%), 3 months (42.9%), and 6 months (21.9%) posttreatment; 93/105 (88.6%) remained symptom-free after discontinuation. Symptoms stabilized in 148/304 (48.7%) patients continuing diet and lifestyle modifications with/without medication. Fluctuating relief and chronic course occurred in 21/304 (6.9%) and 30/304 (9.9%) despite drug class changes. Binary logistic regression revealed baseline IFOS classification as a significant predictor of complete response (P = .038, OR = 1.518, 95% CI [1.024-2.251]).
Conclusion:
Several LPRD patterns were identified: 34.5% achieved complete remission, 48.7% showed sustained symptom reduction, and 16.8% had fluctuating/chronic symptoms despite drug class changes. Baseline IFOS score predicts therapeutic trajectory and outcomes.
Related Concept Videos
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:25Gastroesophageal Reflux Disease
01:23Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...